EU drug legislation
This article was originally published in The Tan Sheet
Executive Summary
European Parliament adopts legislation allowing for an additional year of data exclusivity for OTC switch drugs April 30. Member states have until Oct. 30, 2005 to implement provisions of the new pharmaceutical legislation package. An additional year of data exclusivity for a new indication of a well-established substance also is enacted in the legislation, "provided that significant pre-clinical or clinical studies were carried out in relation to the new indication." The legislation initially allowed for three years of additional data exclusivity but was amended before its adoption (1"The Tan Sheet" Jan. 5, 2004, p. 9)...
You may also be interested in...
EU Revised Legislation Provides One-Year Exclusivity For OTC Switches
Rx-to-OTC switches in the European Union will be provided one year of data exclusivity, instead of the previously proposed three-year period, in a proposed amendment to EU pharmaceutical legislation recently approved by the European Parliament
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.